Buprenorphine alone and in combination with naloxone in non-dependent humans

Linda L. Weinhold, Kenzie L. Preston, Magi Farre, Ira A. Liebson, George E. Bigelow

Research output: Contribution to journalArticle

Abstract

This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalDrug and alcohol dependence
Volume30
Issue number3
DOIs
StatePublished - Aug 1992

Keywords

  • abuse liability
  • buprenorphine
  • human
  • naloxone
  • opioid

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Buprenorphine alone and in combination with naloxone in non-dependent humans'. Together they form a unique fingerprint.

  • Cite this